Purpose: To identify a prognostic gene signature for patients with human papilloma virus (HPV)-negative oral squamous cell carcinomas (OSCC).
Introduction
Recent studies are now starting to reveal the molecular subclassifications of head and neck squamous cell carcinomas (HNSCC) which may help inform treatment options and prognosis. For example, human papilloma virus (HPV)-driven oropharyngeal tumors are associated with better treatment response and prognosis than HPV-negative oropharyngeal tumors (1) . On the other hand, HPV-negative tumors, which typically arise in older patients with a history of extensive tobacco use, are more likely to carry TP53 mutations (2) . Immunohistochemical staining for p16, a surrogate marker of HPV type 16 status (3, 4) , with or without HPV testing, is now being applied clinically to oropharyngeal tumors to aid in assessing treatment responsiveness. In contrast, whereas HPV presence in the oropharynx portends better survival, we need better biomarkers to help prognosticate HPV-negative oral cavity and oropharyngeal tumors. Over the past decade, many studies have documented the use of gene expression signatures based on transcriptomic profiling to improve prognostication in many cancers. Specifically, gene expression tests, such as MammaPrint (5) and Oncotype DX (6, 7) , are used clinically to guide treatment decisions for patients with breast and colon cancer, respectively. We previously identified and validated a 131-gene signature (representing 108 unique known genes) that can distinguish clinically normal oral epithelium, oral dysplasia, and oral squamous cell carcinoma (OSCC) that were consisted of 70% oral cavity cancer and 30% oropharyngeal cancer (8) . Furthermore, we found that this signature was associated with OSCC-specific survival (9) . In the current study, we sought to validate the association of the 131-gene signature with survival in an independent population and to extend our findings to determine whether a subset of this signature could aid in predicting the survival of patients with HPV-negative OSCCs.
Materials and Methods

Datasets
Expression profile datasets from the Fred Hutchinson Cancer Research Center (FHCRC, Seattle, WA) and from the University of Texas M.D. Anderson Cancer Center (MDACC, Houston, TX) were used. The FHCRC dataset, used for discovery, comprised the gene expression profiles of 167 tumor samples from patients with OSCCs and 45 normal oral mucosa samples from patients without oral cancer, all treated at the University of Washington Medical Center (Seattle, WA), the Harborview Medical Center (Seattle, WA), or the Veterans Affairs Puget Sound Health Care System during 2003 to 2007. The FHCRC dataset also contained information on patient demographics, medical and lifestyle history, vital status, cause of death, and tumor characteristics, including tumor site, stage, and HPV status. The specimen collection, storage protocols and assays for specimen processing, and generation and normalization of raw expression data were conducted as previously described (8) . The MDACC dataset, used for validation, contained the gene expression profiles of 103 samples generated from residual tumor tissue, taken from the MDACC Head and Neck Tumor Bank. Demographic characteristics, tumor site, stage, vital status, and cause of death were abstracted from the medical record and the MDACC Tumor Registry. The gene expression and other data from these tissue samples were analyzed under protocol DR09-0664, and de-identified data were shared with the FHCRC under MT2010-6749. Among 103 samples from the MDACC dataset, 74 were cancer samples from patients with OSCCs, 24 were matched normal oral samples from patients with OSCCs, and 5 were normal oral samples from other patients with cancer treated in the MDACC Head and Neck Center. The gene expression data obtained from the MDACC were extracted and normalized, also using the gcRMA algorithm but as implemented in Partek Genomics Suite software. The microarray data can be found in the Gene Expression Omnibus database under the accession numbers GSE41613 and GSE42743
Statistical methods
Validation of the 131-gene signature association with survival. We have previously reported that the principal component (PC) scores calculated from the 131 genes were associated with OSCC-specific and overall survival (9) . To validate these results in the MDACC dataset, we conducted a principal component analysis (PCA) of the 131 genes for all 103 samples using R software version 2.8.1, function prcomp. We dichotomized the first PC score at the median and compared the high and low PC score groups using Kaplan-Meier curves for overall survival and cumulative incidence curves for OSCC-specific mortality using R packages survival and cmprsk. We then conducted a Cox proportional hazard regression analysis comparing the group with high and low PC score.
Development of a 13-gene signature prediction model for survival in HPV-negative OSCC patients. To build a prediction model for OSCC-specific survival unique to the patients with HPV-negative OSCCs, we conducted regularized survival analysis using the data from 97 patients with high-risk HPV-negative OSCC in the FHCRC dataset. Highrisk HPV that we tested included HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68 as previously described (10) . To select the most useful predictors among the 131 genes, we used the L1-penalized (Lasso) Cox proportional hazard regression model (R package glmnet; ref. 11). In this model, the L1 penalty parameter controls the sparsity (number of non-zero parameters or number of selected predictors) of the final estimated model. The larger this parameter is, the fewer the predictors will be selected. We used 10-fold cross-validation partial likelihood scores to choose the optimal L1 penalty parameter. Specifically, we first randomly split the data into 10 groups of roughly equal size. Then, for a given candidate L1 penalty parameter, we used data from 9 of the 10 groups to fit the model and calculated the corresponding partial likelihood score of the fitted model on the remaining group, and we repeated this for every possible collection of 9 groups The final performance score of each candidate penalty parameter was the summation of the log partial likelihood scores from all 10 cross-validate iterations. We examined a sequence of candidate L1 penalty parameters and selected the one returning the best cross-validation performance score. We then refitted the model using all the data with the optimal L1 penalty parameter. The resulting model included 13 genes.
Translational Relevance
Mounting evidence suggests that head and neck squamous cell carcinoma is not a single disease but rather can be further subclassified molecularly. Subsite-specific etiologic and prognostic markers, such as human papilloma virus (HPV), are emerging. Patients with HPVpositive oropharyngeal carcinomas are known to have better treatment response and survival. In contrast, there are no currently defined molecular markers to assess treatment responsiveness for HPV-negative oral squamous cell carcinomas (OSCC). Recent works including our own have shown that gene expression profiling can identify subgroups of patients with poor survival. Thus, gene expression signatures show promise as clinical tools to help guide treatment intensification. In this study, we built on our previous molecular work to subclassify OSCCs and have identified and validated a prognostic 13-gene signature that showed a higher ability than tumor stage in predicting survival for patients with HPV-negative OSCCs. This is the first demonstration of a gene set that provides prognostic information beyond American Joint Committee on Cancer stage for this subgroup of tumors.
While L1-penalized regressions are helpful for variable selection, the coefficient estimation from such models tends to bias toward zero when a large degree of regularization (large value of L1 penalty parameter) is used to identify the best model. Therefore, to obtain good coefficient estimation for the 13 selected transcripts in the Cox regression model, we further fit a L2-penalized Cox regression model (12) . Compared with the ordinary Cox regression model, the L2-penalized version provides good tradeoff between biases and variances and usually improves the prediction error. Again, the amount of L2 penalty applied was determined through a 10-fold cross-validation. With the estimated coefficients from the selected L2 regression model, a continuous risk score was generated for each subject based on the expression of the 13 genes. We then fit 3 Cox regression models, each with the following independent variables: (i) age, gender, treatment, 13-gene risk score; (ii) age, gender, treatment, stage; and (iii) age, gender, treatment, stage, 13-gene risk score. Tumor stage was dichotomized as American Joint Committee on Cancer (AJCC) stage I/II and III/IV, treatment was dichotomized as unimodality and multimodality, and age was categorized as <50, 50-59, 60-69, and !70 years.
Validation of the 13-gene risk score-based prediction models for oral cavity cancer-specific survival in the MDACC dataset. HPV status was not available in the MDACC dataset. We therefore included only patients with oral cavity cancer (n ¼ 71) to determine the 13 genes' performance in predicting oral cavity cancer-specific survival. First, for each patient with oral cavity cancer in MDACC dataset, we calculated a risk score based on his/her tumor expression levels of the 13 genes. We then applied the Cox regression models developed earlier to predict oral cavity cancerspecific survival for the MDACC patients. A 2-year oral cavity cancer-specific survival receiver operating characteristic (ROC) curve was generated for each model using R package CompRisksROC, which accounts for competing risks (13) , and the area under the curve (AUC) was calculated to quantify the predictive ability of each model. Leave-10-out jackknife was used to calculate 95% confidence interval (CI) for the AUC estimates. In addition, we divided the patients into 2 groups using the risk score median as the cutoff point. The cumulative incidence curve for oral cavity cancer-specific mortality was plotted for each group, and the equality of the cumulative mortality between the risk groups was tested using R package cmprsk, which implements the K-sample test described by Gray (14) .
Validation of 13 genes expression using Nanostring nCounter Gene Expression assay
The expressions of the 13 genes were further validated using a custom-designed NanoString nCounter Gene Expression Assay (Nanostring Technologies). The assay is designed to provide a sensitive and reproducible method for detecting gene expression with the use of molecular barcodes called nCounter Reporter Probes in a multiplex format without reverse transcription or amplification (15) (16) (17) . A custom designed nCounter GEX codeset was developed for the 13 genes along with seven housekeeping genes (ALAS1, GAPDH, RPL27, RPS18, SDHA, TBP, and TUBA1B) previously shown to be stably expressed in HNSCCs (18) . When possible, the probes in the codeset were targeted near the sequence region of the Affymetrix probe target region. We used the Nanostring nCounter Gene Expression assay to test RNA samples from 36 fresh tumors preserved in RNAlater that were used in the generation of the signature and compared the NanoString results with the Affymetrix results. Approximately 100 ng of total RNA was processed on a nCounter Analysis System as per NanoString Gene Expression Assay standard protocol. To control for assay efficiency, 6 spike-in RNA controls were included in each sample ranging from 0.125 to 128 fmol/L. All samples were processed at Nanostring Technologies in Seattle, WA. To obtain the transcript counts, the raw data are first normalized using the geometric mean of the counts (POSA-F) from spiked-in synthetic RNA internal positive controls to account for systematic variation in reporter purification and imaging from lane-to-lane. These normalized counts are further corrected for mRNA input by using the reference gene counts in each assay. Our data showed that RPL27, RPS18, TBP, and ALAS1 had the smallest SD and % coefficient of variation (CV) across all samples. Thus, we normalized the transcript counts against the average of these 4 housekeeping genes. We then used Pearson correlation to test the correlation between gene expression level from Affymetrix arrays and Nanostring nCounter Gene Expression assay.
Results
Patient characteristics
Selected characteristics of the 97 patients with high-risk HPV-negative OSCCs from the FHCRC and 71 patients with oral cavity cancer from the MDACC studies are presented in Table 1 . The majority of the patients from both institutions were older than 50 years. The proportions of males and of current smokers were comparable between the institutions. There was a higher proportion of advanced stage cancers than early-stage cancers and a higher proportion of patients treated with multimodality than unimodality in both institutions. The patients with OSCCs from the 2 institutions were followed for similar lengths of time: median of 26.3 months (range, 0.2-64.9 months) at the FHCRC and median of 26.9 months (range, 0.2-92.6 months) at the MDACC, among patients who were known to be alive at the end of the respective studies.
Survival analysis of the 131-gene signature using the MDACC dataset Figure 1 shows Kaplan-Meier curves of overall survival and cumulative incidence curves for OSCC-specific mortality for the high and low first PC score groups. Patients with high PC scores had significantly poorer overall survival than the patients with low first PC scores (P ¼ 0.0075). At 3 years, the estimated proportion dying (AESE) from all causes for patients with high PC scores was 57.6% (AE10.4%) compared with 20.3% (AE7.4%) for the patients with low PC scores. The cumulative OSCC-specific mortality was also significantly higher for the patients with high PC scores than for the patients with low PC scores (P ¼ 0.031). The estimated cumulative OSCC-specific mortality (AESE) at 3 years for patients with high PC scores was 44.6% (AE8.7%) compared with 24.1% (AE9.8) for patients with high PC scores. Cox proportional hazard regression analyses showed that patients with high PC scores, compared with patients with low PC scores, had significantly higher overall and OSCC-specific mortality, with HRs of 2.98 (95% CI, 1.53-5.81) and 3.41 (95% CI, 1.38-8.40), respectively. The HRs remained significant after adjusting for age, gender, and tumor stage. The respective adjusted HRs were 2.64 (95% CI, 1.34-5.22) and 3.12 (95% CI, 1.24-7.87) for overall and OSCC-specific mortality.
Development and validation of a 13-gene prediction model for the survival of HPV-negative OSCC patients
Using an L1-penalized Cox proportional hazard regression method on the FHCRC dataset, we identified a prediction model with 13 genes. The gene symbols and coefficients from the L2-penalized Cox regression model of the 13 genes are presented in Table 2 . Figure 2 shows cumulative incidence curves for oral cavity cancer-specific mortality by high-and low-risk scores in the MDACC dataset. Patients with high risk scores had significantly higher oral cavity cancer-specific mortality than patients with low-risk scores (P ¼ 0.0253). The estimated proportions of patients dying from oral cavity cancer (AESE) at 2 years for high-and low-risk scores were 47.1% (AE9.24%) and 6.35% (AE4.42%), respectively. The unadjusted HR from a Cox proportional hazard regression analysis comparing patients with high-and low-risk scores was 3.61 (95% CI, 1.45-9.01; P ¼ 0.0059). The HR adjusting for age, gender, tumor stage, and treatment modality was also significant (HR, 3.72; 95% CI, 1.37-10.10; P ¼ 0.0099). The ROC curves for survival from patients with oral cavity cancer at 2 years for 3 prediction models (stage, stage plus risk score, and risk score) adjusting for age, gender, and treatment modality are shown in Fig. 3 . The AUC for the prediction model with tumor stage was 0.54 (95% CI, 0.48-0.62).
Incorporating a term for the 13-gene risk score into the model with tumor stage substantially and significantly improved the ability to predict survival from oral cavity cancer at 2 years from 0.54 to 0.79 (95% CI, 0.75-0.87; P < 0.001). The risk score itself, without tumor stage, also had a significantly higher predictability of survival in patients with oral cavity cancer than the tumor stage; the AUC for the model with risk score was 0.78 (95% CI, 0.74-0.86) compared with 0.54 for the model with tumor stage (P < 0.001).
Validation with Nanostring nCounter Gene Expression assay
We found good-to-excellent correlation between gene expression level from Affymetrix array and from Nanostring nCounter assay across samples for all probes except for a For the genes with positive coefficients, a higher expression level was associated with a higher risk of OSCC-specific mortality; and, for the genes with negative coefficients, a lower expression level was associated with a higher risk of OSCC-specific mortality.
b
Fold changes comparing patients with high-risk score to patients with low-risk score, based on the original expression scale Figure 2 . Cumulative incidence curves for oral cavity cancer-specific mortality of the 71 patients with oral cavity cancer in the MDACC dataset by group dichotomized by median of the risk score. Figure 3 . ROC curves comparing the ability to predict 2 years oral cavity cancer-specific survival of the 3 prediction models adjusted for age, gender, and treatment in the 71 patients with oral cavity cancer from the MDACC dataset. The jackknife P value testing the AUCs between the model containing term for "risk score" and the model containing term for "stage" is <0.001; the P value comparing the models containing terms for both "risk score and stage" and the model containing the term "stage" is <0.001. 
Discussion
We previously reported on a 131-gene signature which identified patients with OSCCs with poor survival and that, when used in combination with AJCC stage, predicted survival better than AJCC stage alone (9) . In this study, we showed that this 131-gene signature is also predictive of OSCC survival in an independent dataset from the MDACC. Moreover, in keeping with the fact that HPV is already a useful biomarker for oropharyngeal carcinomas (19) and the that a survival gene signature would be most relevant for HPV-negative OSCCs, we used the 131 genes to identify a subset of genes, which included 13 genes, that was most predictive of OSCC-specific survival in patients with HPVnegative OSCCs. We showed that this 13-gene signature is strongly associated with OSCC-specific survival in the MDACC dataset and that OSCC-specific survival estimates using this signature were substantially better than those using AJCC stage alone. These findings represent the first development and validation of a survival gene signature for HPV-negative OSCCs using independent datasets from 2 institutions and document the generalizability of our previous 131-survival gene signature for patients with OSCCs. If further validated in multicenter studies, the 13-gene signature may help physicians and patients make better personalized treatment choices. For example, patients with stage I/II disease that test in the high-risk category could be considered for treatment intensification with multimodality therapy and vice versa for those with stage III/IV disease. In our previous study, we had used stepwise regression to identify the following subset of genes from the 131-gene signature that were most strongly associated with OSCCspecific survival while adjusting for age, sex, stage, HPV status, treatment intensity, and comorbidity (9): LAMC2, OSMR, SERPINE1, OASL, SLC16A1, KLF7, THBS1, HOMER3, GRP68, PDPN, AKRD35, CDH3, and EPS8L1. In this study, we also sought to narrow our list of genes, but with 2 main analytic differences: (i) we restricted the cohort to patients with HPV-negative OSCC in the training set and (ii) the methodology to identify the subset of 13 genes was substantially different. Still, 6 genes overlapped between these 2 analyses (LAMC2, OSMR, SERPINE1, THBS1, SLC16A1, and OASL) and all but one of these were among the genes most strongly associated with survival in our previous report. These genes all play a role in cell invasion and motility, cell-to-cell signaling, signal transduction, and proliferation, processes essential to metastasis and cancer progression (20) (21) (22) (23) (24) (25) (26) (27) (28) . Many of the other 7 genes identified in this study have also been implicated in processes relevant to cancer. For example, a recent study identified tetranectin (CLEC3B) to be downregulated in the serum and saliva of metastatic versus primary OSCC (29) . NREP (P311) has been shown to be overexpressed in invasive glioma cells, localized in focal adhesions, and is constitutively serinephosphorylated; decreased phosphorylation has been associated with migration-activated glioma cells (30) . MYH11 is a member of the myosin family, and we have previously identified myosin 5A as a potential biomarker of occult metastasis in OSCCs (31) . Mutations in this gene have been found to be associated with intestinal, breast, and prostate cancer (32, 33) . TPPP is thought to play a role in microtubule assembly and stabilization (34) , and a gain in its chromosomal location 5p15.33 has been associated with high-grade bladder cancer (35) . Interestingly, ZDHHC11, in our 13-gene signature, shares this location with TPPP.
A limitation of our study is the lack of information on HPV status in the MDACC dataset that we used for validation. As oral cavity tumors are much less likely to be associated with HPV infection (36, 37), we limit the validation set to oral cavity tumors only.
In conclusion, we have identified and validated a 13-gene expression signature that is strongly predictive of survival in patients with HPV-negative OSCCs. Importantly, (i) the signature adds substantial predictive information beyond stage, and (ii) the small number of genes in the signature should make it more amenable to develop a cost-effective clinical test. Together, these data provide strong justification to proceed with multi-institutional trials to determine whether this signature is effective as a prognostic marker.
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